NCT00522548 - Myfortic or CellCept Gastrointestinal Effects in African American Kidney Recipients | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 31, 2007

Primary Completion Date

January 31, 2011

Study Completion Date

January 31, 2011

Conditions

Transplants and Implants

Interventions

DRUG

Enteric coated mycophenolate sodium

Patients in this group will receive Myfortic (enteric-coated mycophenolate sodium) in combination with Thymoglobulin (rabbit Anti-thymocyte globulin) induction immunosuppression, Prograf (tacrolimus) or its generic equivalent, and corticosteroid immunosuppression.

DRUG

Mycophenolate mofetil

Patients in this group will receive CellCept (mycophenolate mofetil) or its generic equivalent formulation manufactured by Sandoz, in combination with Thymoglobulin (rabbit Anti-thymocyte globulin) induction immunosuppression, Prograf (tacrolimus) or its generic equivalent, and corticosteroid immunosuppression.

Trial Locations (1)

19104-4322

Hospital of the University of Pennsylvania, Philadelphia